Resolving the controversies surrounding lymphatic mapping in breast cancer
2008 (English)In: Future Oncology, ISSN 1479-6694, Vol. 4, no 5, 681-688 p.Article, review/survey (Refereed) Published
Sentinel lymph node biopsy has rapidly become the standard of care in the primary treatment of breast cancer. Most of the initially identified potential contra indications towards the procedure, such as nonpalpability, large tumor size, pregnancy and being previously operated in the breast or axilla, have been ruled out, whereas multifocality represents an unsolved problem. There is no consensus about the best use of the technique in patients receiving neoadjuvant treatment. There is no place for sentinel lymph node biopsy in pure ductal carcinoma in situ, but it can be used for large high-grade in situ cancer diagnosed through core biopsy, especially if a mastectomy is planned. Morbidity is low, and the recurrence rates reported so far are reassuring. However, long-term results are lacking, and results from ongoing randomized trials are awaited.
Place, publisher, year, edition, pages
2008. Vol. 4, no 5, 681-688 p.
axillary lymph node dissection, breast cancer, sentinel lymph node biopsy
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-142377DOI: 10.2217/147966126.96.36.1991ISI: 000261775200016OAI: oai:DiVA.org:uu-142377DiVA: diva2:387436